Intercept (ICPT) Competitive Risk from Galectin (GALT) 'Deminimus' - BMO Capital
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
